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Abstract. The T790M mutation in the epidermal growth 
factor receptor (EGFR) gene is known to be associated with the 
acquired resistance of lung adenocarcinoma patients to EGFR-
tyrosine kinase inhibitors (EGFR-TKIs). The minor T790M 
mutant allele is occasionally detected in EGFR-TKI-naive 
tumor samples, yet findings concerning the clinical impact 
of the minor T790M mutation vary among previous studies. 
In the present study, we assessed the clinical impact of the 
minor T790M mutation using a novel, highly sensitive assay 
combining high-resolution melting (HRM), mutant-enriched 
PCR and co-amplification at a lower denaturation temperature 
(COLD)-PCR. We determined the T790M mutational status in 
146 surgically resected lung adenocarcinomas without a history 
of EGFR-TKI treatment using mutant-enriched COLD-HRM 
(MEC-HRM) and standard HRM assays. The sensitivities 
of the MEC-HRM and standard HRM assays for the detec-
tion of T790M-mutant alleles among wild-type alleles were 
0.01 and 10%, respectively. Although the T790M mutation 
was not detected using a standard HRM assay, we identified 
19 (13%) T790M mutations using the MEC-HRM assay and 
defined these 19 mutations as minor T790M mutations. The 
proportion of T790M alleles was <0.1% in 17 (84%) of the 19 
samples. Multivariate analyses revealed that a minor T790M 
mutation was significantly associated with the presence of 
EGFR exon 19 deletions or the L858R mutation (both of which 
are drug-sensitive EGFR mutations) (P=0.04). In conclusion, 
the minor EGFR T790M mutations were present in 13% of 
EGFR-TKI-naive surgically resected lung adenocarcinomas 
and were associated with drug-sensitive EGFR mutations.
Introduction
Activating mutations of the epidermal growth factor receptor 
(EGFR) gene are characteristic genetic alterations in non-
small lung cancer (NSCLC) patients, particularly in those with 
lung adenocarcinomas (1-3). EGFR exon 19 deletions or the 
exon 21 L858R mutation account for more than 90% of all 
EGFR mutations (4,5). Of particular importance, these muta-
tions are known as predictors of a favorable clinical outcome 
in response to treatment with EGFR-tyrosine kinase inhibi-
tors (EGFR-TKIs) (1,2). Although ~80% of NSCLC patients 
with drug-sensitive EGFR mutations such as EGFR exon 19 
deletions or the exon 21 L858R mutation initially show satis-
factory responsiveness to EGFR-TKI treatment (1,2), acquired 
resistance to EGFR-TKIs occurs in most cases (6). Half of all 
resistance to EGFR-TKIs is caused by an acquired T790M 
mutation in exon 20 of the EGFR gene (7-9). The T790M 
mutation has been reported to cause EGFR-TKI resistance by 
sterically hindering the binding site of gefitinib and erlotinib, 
two first-generation EGFR-TKIs (7), thereby causing a relative 
decrease in binding with EGFR-TKIs (10).
The T790M mutation has been detected in some patients 
who have not been treated with EGFR-TKIs (11-16). Since the 
incidence of a T790M mutation has been reported to range 
from 0.02 to 0.05% in all surgically resected NSCLC patients 
based on studies using direct sequencing (2,17), it is difficult to 
clarify the association due to the T790M mutation and clinico-
pathological factors because of the limitation in the number of 
cases. Using highly sensitive assays, the clinical impact of the 
minor T790M mutation in NSCLC patients with EGFR-TKI 
treatment has been previously investigated (11,14,15). However, 
the impact on EGFR-TKI-naive NSCLC patients has not been 
adequately investigated (12,13,16). Recently, various therapies 
to overcome the T790M mutation are being developed. These 
include next generation EGFR-TKIs (18) and combination 
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therapies (19). Minor T790M mutated clones are enriched by 
EGFR-TKI treatment (12,16); thus, early detection of a minor 
T790M mutation using a highly sensitive assay may be useful 
for predicting the cause of resistance to EGFR-TKIs and for 
selecting optimum therapeutic strategies.
In the present study, we determined the T790M mutational 
status using high-resolution melting (HRM) analysis combined 
with mutant-enriched (12,20) and co-amplification at lower 
denaturation temperature (COLD)-polymerase chain reactions 
(PCRs) (21-24) to investigate the relationship between the 
presence of minor T790M mutations and clinicopathological 
factors in EGFR-TKI-naive lung adenocarcinoma patients 
with pulmonary resection.
Materials and methods
Clinical samples, cell lines and DNA extraction. We studied 
146 patients with lung adenocarcinomas who underwent 
surgical resection without a preoperative history of EGFR-TKI 
treatment at our institute between 2006 and 2009. Approval of 
the Institutional Review Board and the informed consent of 
each patient were obtained. After pulmonary resection, fresh 
tissue was immediately frozen and stored at -80˚C. DNA was 
extracted from the frozen tissue using proteinase K treatment 
followed by phenol-chloroform extraction (25). We also used 
a human bronchial epithelial cell line (HBEC-5KT) harboring 
the wild-type EGFR gene and the NCI-H1975 cell line 
(H1975) harboring the EGFR mutations L858R and T790M 
as negative and positive controls, respectively. These cell lines 
were kindly provided by Dr Adi F. Gazdar (The University 
of Texas Southwestern Medical Center at Dallas, Dallas, TX, 
USA). DNA of the cell lines was extracted using the DNeasy 
Blood & Tissue kit (Qiagen, Hilden, Germany).
Plasmids containing exon 20 of the EGFR gene. We used a 
plasmid containing EGFR exon 20 with the T790M mutation, 
which is one of the standardized plasmids containing each 
of the EGFR mutations occurring in the exons, and was used 
in a study by Goto et al (26). We also constructed a plasmid 
containing wild-type EGFR exon 20 using the TOPO TA 
Cloning Kit (Invitrogen, Carlsbad, CA, USA) as previously 
reported by us (27). The sequences of each plasmid were 
confirmed by direct sequencing.
Detection of EGFR exon 19 deletions and the L858R mutation. 
EGFR exon 19 deletions and the exon 21 L858R mutation were 
examined using a restriction fragment length polymorphism 
(RFLP) assay without the enrichment of mutant alleles, as 
previously reported by us (20). We defined these EGFR exon 
19 deletions and the exon 21 L858R mutation as drug-sensitive 
EGFR mutations.
Detection of the EGFR T790M mutation. Mutant-enriched 
COLD-HRM (MEC-HRM) is a two-step PCR-based assay 
combining a standard HRM assay with a mutant-enriched 
PCR (12,20) that enriches the mutant allele by the intermittent 
restriction digestion of the wild-type allele and a COLD-PCR 
(21) that enriches the mutant allele by means of the difference in 
melting temperatures between the mutant and wild-type alleles. 
The principle of the MEC-HRM assay is shown in Fig. 1A.
As the first step, conventional PCR was performed to 
amplify the target region (129 base pairs), including codon 790 
Figure 1. (A) Principle of the mutant-enriched COLD-HRM (MEC-HRM) assay. In the first step (left box), the upper box indicates the conventional PCR step 
for the amplification of EGFR exon 20, including codon 790. The mismatched site of the AS1 primer to introduce the CGCG sequence (framed) is emphasized 
with light gray shading. The exchanged bases are emphasized with bold print. An asterisk indicates the SNP site. The lower box indicates the step for the 
selective digestion of the wild-type amplicon. The crosses are applied on reduced amplicons. After digestion, the product that includes the mutant amplicon 
and residual undigested wild-type amplicon is used for the second step. The upper box indicates the first step of the real-time PCR for the amplification of 
the template product. The mismatched site of the S2 primer to diminish the influence of SNP is emphasized in light gray shading. The lower box indicates the 
second step, which is a COLD-PCR step for the selective amplification of the mutant. The Td (78.0˚C) was lower than Tm of the wild-type amplicon; thus, they 
were not denatured and the primers were not annealed. The final products were analyzed using an HRM analysis. 
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of the EGFR gene, using the GeneAmp® 9700 thermal cycler 
(Applied Biosystems, Foster City, CA, USA). The forward 
primer sequence was 5'-ACTGACGTGCCTCTCCCTCC-3' 
(S1). The reverse primer sequence was 5'-CGAAGGGCATG 
AGCC*GC-3' (AS1), harboring one mismatched site (* T to C) 
to introduce the CGCG sequence into the amplicon of the 
wild-type. The final volume of the PCR mixture was 10 µl 
contained 100 ng of sample DNA, 150 nmol of deoxynucleo-
tide triphosphate, 2 pmol of each primer, and 1 unit of 
HotStarTaq DNA Polymerase Plus (Qiagen). The PCR condi-
tions were as follows: an initial denaturation step at 95˚C for 
5 min, followed by 35 cycles of 94˚C for 20 sec, 60˚C for 
30 sec, and 72˚C for 20 sec. Diluted PCR products (100-fold 
dilution with distilled water) were treated with the restriction 
enzyme BstUI (New England BioLabs, Ipswich, MA, USA), 
which digests the wild-type allele but not the mutant allele, for 
16 h at 60˚C, resulting in the enrichment of the mutant alleles, 
as previously reported by us (12).
After the first step, the second step (COLD-PCR, including 
melting curve analysis) was performed using the StepOnePlus™ 
real-time PCR system (Applied Biosystems). The forward 
primer sequence was 5'-CCTCCACCGTGCAC*CTCATC-3' 
(S2). Since one SNP site (rs1050171 A/G) exists in the S2 
primer sequence, we designed a mismatched-base (* C) at the 
SNP position to diminish the influence of the SNP (28). We 
used the AS1 primer as a reverse primer. The final volume of 
the PCR mixture was 20 µl, containing 10 µl of MeltDoctor™ 
Master Mix (Applied Biosystems), 12 pmol of each primer and 
Figure 1. Continued. (B) Principle of standard HRM assay. The box indicates the real-time PCR step using the S2 primer (forward) and the AS1 primer 
(reverse). The real-time PCR conditions are as follows: an initial denaturation step at 95˚C for 10 min, and an amplification step for 55 cycles (95˚C for 15 sec, 
60˚C for 60 sec). The final products are analyzed using HRM analysis. (C) Principle of COLD-HRM assay. The upper box indicates the first step of 18 cycles 
of real-time PCR for the amplification of the template product, and the lower box indicates the second step, which is a COLD-PCR step, for the selective 
amplification of the mutant allele. In the second step, the denaturing temperature (Td) is decreased to 78˚C and amplification is performed for 30 cycles. The 
final products are analyzed using HRM analysis. (D) Principle of mutant-enriched HRM assay. In the first step (left box), conventional PCR and digestion are 
performed, similar to that shown in the left box of (A). The second step (right box) is performed in the same manner as standard HRM (B) using the products 
from the first step. Forty cycles are used for the mutant-enriched HRM assay, instead of 55 cycles for the standard HRM assay.
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1 µl of the first-step product. The real-time PCR conditions 
were as follows: an initial denaturation step at 95˚C for 10 min, 
18 cycles for the first round of standard amplification (95˚C for 
15 sec, 60˚C for 60 sec), and 30 cycles for the second round of 
amplification to enrich the mutant-amplicons (78˚C for 15 sec 
and 60˚C for 60 sec). The denaturing temperature (Td) of the 
COLD-PCR step (78˚C) was determined using a melting curve 
analysis of the standard HRM [the melting temperatures (Tm) 
of the mutant-type and wild-type amplicons were 78˚C and 
79.2˚C, respectively] and an evaluation of the sensitivity of 
COLD-PCR from Td 79.2 to 78˚C every 0.2˚C. After the 
amplification step, a melting curve was generated and analyzed 
using HRM software ver. 3.0.1 (Applied Biosystems).
We also performed standard-HRM, COLD-HRM and 
mutant-enriched HRM assays. The principles of these three 
assays are provided in Fig. 1B-D. All the samples, including 
the standard DNA mixtures, were analyzed in triplicate in all 
the assays. The sensitivities of all four assays were determined 
using multiple DNA mixtures of T790M mutant and wild-type 
alleles (0.01, 0.05, 0.1, 1, 10, 20 or 50% of T790M mutant allele).
Statistical analysis. Chi-square tests or Fisher's exact tests 
were used to examine the differences in categorical factors 
across groups, as appropriate. The multivariate logistic regres-
sion model was used to identify clinicopathological factors 
that might independently predict the presence of T790M 
mutations.
After pulmonary resection, imaging studies were repeated 
every 3 months for at least 2 years and every 6 months thereafter 
for 3 years. After 5 years, medical examinations were repeated 
every year. The progression-free survival (PFS) was calculated 
from the date of surgery until confirmed disease recurrence or 
death. The overall survival (OS) was calculated from the date 
of surgery until the date of death or the last follow-up. The 
survival curve was calculated using the Kaplan-Meier method, 
and the difference between groups was compared using the 
log-rank test. Multivariate analyses were performed using the 
Cox proportional hazard model. All the data were analyzed 
using JMP, version 9.0.0 (SAS Institute Inc., Cary, NC, USA). 
All the statistical tests were two-sided, and probability values 
(P) <0.05 were considered statistically significant.
Results
Sensitivity of each assay for the detection of the T790M muta-
tion. The MEC-HRM assay was able to detect the T790M 
mutant allele in the sample with a mutant allele content of 
0.01%. In other words, it detected the mutant allele in the 
presence of a 10,000-fold background of wild-type allele 
(Figs. 2 and 3). Meanwhile, the detection limits of standard 
HRM, COLD-HRM and mutant-enriched HRM assays were 
a mutant allele content of 10, 1 and 0.1%, respectively (Fig. 4). 
Based on these data, we investigated the T790M mutation in 
146 clinical samples using the standard HRM using a DNA 
mixture with T790M content of 10% as a positive control, and 
the MEC-HRM assays using a DNA mixture with T790M 
content of 0.01% as a positive control. Clinical samples and 
positive controls were investigated in the same plate in tripli-
cate. When all three signals from a clinical sample exceeded 
the maximal signal from the control, the sample was identified 
to be positive for the T790M mutation (Fig. 2).
EGFR mutations in the clinical samples. Drug-sensitive EGFR 
mutations were found in 54 (37%) of the 146 lung adenocar-
cinomas (26 exon 19 deletions and 28 L858R mutations). 
Drug-sensitive EGFR mutations were significantly associated 
with females (P<0.01) and never-smokers (P<0.01).
Although standard HRM did not detect any EGFR T790M 
mutations, EGFR T790M mutations were detected in 19 (13%) 
of the 146 lung adenocarcinomas using the MEC-HRM assay. 
Thus, these 19 patients were defined as harboring minor 
T790M mutations. We confirmed that these 19 tumor samples 
had a tumor cell composition of at least 20% by examining the 
proportion of tumor cells in the tissue using hematoxylin and 
eosin staining. Next, we determined the dosage of the T790M 
mutant allele in 19 mutant samples by reanalyzing these 
samples and comparing them with 10, 1, 0.1 and 0.01% stan-
dard T790M mutant DNA mixtures. We subcategorized the 
Figure 2. Sensitivity of MEC-HRM assay and representative clinical samples. (A) Difference plot showing the sensitivity of the MEC-HRM assay. We selected 
wild-type DNA (HBEC-5KT) for the standard of difference plots (horizontal line). Each percentage indicates the proportion of T790M-mutant DNA out of 
wild-type DNA. Consequently, the MEC-HRM assay was able to detect a T790M-mutant DNA (H1975) level of 0.01% among wild-type DNA (HBEC-5KT). 
(B) The red curves indicate a DNA mixture containing 0.01% H1975 DNA among HBEC-5KT DNA. The green curves indicate the clinical samples deter-
mined as T790M-negative, and the blue curves indicate the samples determined as T790M-positive. Case 1 contains a 0.01-0.1% proportion of T790M clones, 
and case 15 contains a 0.1-1% proportion of T790M clones.
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19 minor T790M mutations into groups with T790M mutant 
DNA levels corresponding to 0.01-0.1%, 0.1-1% and 1-10%. As 
shown in Table I, 17 of the 19 patients (84%) had a T790M 
mutant allele proportion of <0.1%.
The details of the 19 patients harboring minor T790M 
mutations and the relationships between a minor T790M 
mutational status and clinicopathological factors are shown 
in Tables I and II, respectively. Minor T790M mutation was 
not significantly associated with age, gender, pathological 
stage, smoking history or drug-sensitive EGFR mutations in 
univariate analyses. However, drug-sensitive EGFR mutations 
are considered to be associated with age, gender and smoking 
status (27,29,30); thus, a multivariate analysis was performed 
to identify independent factors associated with a minor T790M 
mutation. Consequently, the minor T790M mutation was found 
to be independently associated with drug-sensitive EGFR 
mutations (OR, 3.0; 95% CI, 1.0-9.0; P=0.04) (Table III).
Regarding the prognostic impact of the minor T790M 
mutation, it was not associated with either the OS or the PFS 
in our cohort (Table IV).
Discussion
In the present study, we determined the T790M mutational 
status using our newly developed, highly sensitive assay, the 
MEC-HRM assay. We previously developed a mutant-enriched 
PCR assay (sensitivity, 0.1%) and found that the T790M muta-
tion was detected in 3.8% of NSCLC patients without a history 
of treatment with EGFR-TKIs (12). Su et al (16) found that 
the T790M mutation was present in 25.2% of EGFR-TKI-
naive NSCLC patients using matrix-assisted laser desorption 
ionization-time of flight mass spectrometry (MALDI-TOF 
MS) (sensitivity, 1.5%), and Oh et al (13) found that the T790M 
mutation was present in 8.2% of EGFR-TKI-naive NSCLC 
Figure 3. Comparison of sensitivities between plasmid and genomic DNA mixes. (A) The MEC-HRM assay was able to detect the T790M mutant allele at 
a level of 0.01% among wild-type alleles using the plasmid mixture. (B) The MEC-HRM assay showed similar sensitivities for the genomic DNA mixtures 
(H1975 and HBEC-5KT) and the plasmid mixtures.
Figure 4. Sensitivities of standard HRM, COLD-HRM and mutant-enriched HRM assays. The difference plots for all three assays are shown. Wild-type DNA 
was used as a negative standard, and the percentages in each figure indicate the proportion of T790M-mutant DNA out of wild-type DNA. Consequently, 
the (A) standard HRM, (B) COLD-HRM and (C) mutant-enriched HRM assays were able to detect T790M-mutant DNA at levels of 10, 1 and 0.1% among 
wild-type DNA, respectively.
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Table I. Details of the 19 T790M-positive patients.
 Age   Pathological Drug-sensitive Proportion of T790M
Case (years) Gender Smoking history stage EGFR mutation clones
  1 59 Male Never-smoker I ex19 del. 0.01-0.1%
  2 75 Male Never-smoker I ex19 del. 0.01-0.1%
  3 75 Female Never-smoker I L858R 0.01-0.1%
  4 75 Female Never-smoker I L858R 0.01-0.1%
  5 79 Female Never-smoker I L858R 0.01-0.1%
  6 60 Female Never-smoker I WT 0.01-0.1%
  7 60 Male Never-smoker III WT 0.01-0.1%
  8 66 Male Smoker I ex19 del. 0.01-0.1%
  9 57 Female Smoker I ex19 del. 0.1-1%
10 76 Male Smoker I ex19 del. 0.01-0.1%
11 82 Male Smoker I L858R 0.01-0.1%
12 58 Male Smoker I L858R 0.01-0.1%
13 56 Male Smoker I WT 0.01-0.1%
14 32 Female Smoker I WT 0.1-1%
15 59 Female Smoker I WT 0.01-0.1%
16 78 Female Smoker I WT 0.01-0.1%
17 68 Male Smoker I WT 0.01-0.1%
18 74 Male Smoker I WT 0.01-0.1%
19 84 Female Smoker II L858R 1-10%
ex19 del., exon 19 deletion; WT, wild-type. Drug-sensitive EGFR mutations include detection of exon19 deletions and the L858R mutation.
Table II. Relationship between minor T790M mutations and clinicopathological factors.
 T790M-positive (n=19) T790M-negative (n=127)
Subsets (n=146) n, (%) n, (%) P-value
Age (median; range) (68; 32-87 years)
  <68 (n=72) 9 (47.4) 63 (49.6) 0.9
  ≥68 (n=74) 10 (52.6) 64 (50.4)
Gender (male vs. female)
  Male (n=71) 10 (52.6) 61 (48.0) 0.7
  Female (n=75) 9 (47.4) 66 (52.0)
Smoking history
  Smoker (n=74) 12 (63.2) 62 (48.8) 0.2
  Never-smoker (n=72) 7 (36.8) 65 (51.2)
Pathological stage
  I  (n=103) 17 (89.5) 86 (67.7) 0.06
  II  (n=12) 1 (5.3) 11 (8.7) (I vs. others)
  III (n=21) 1 (5.3) 20 (15.7)
  IVa (n=10) 0 (0.0) 10 (7.9)
Drug-sensitive EGFR mutation
  Mutant (n=54) 10 (52.6) 44 (34.6) 0.1
  Wild (n=92) 9 (47.4) 83 (65.4)
aStage IV includes 4 recurrent patients. Drug-sensitive EGFR mutations include detection of exon19 deletions and the L858R mutation.
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patients using peptide nucleic acid (PNA)-clamping PCR with 
a melting curve analysis (sensitivity, 0.01%). The present study 
revealed that the MEC-HRM assay could detect the T790M 
mutation in 13% of EGFR-TKI-naive adenocarcinomas. Of 
note, our standard HRM assay (10% sensitivity) did not detect 
any T790M-positive specimens, and we considered all the 
T790M mutations that were detected using the MEC-HRM 
assay to be minor mutations (2,17).
As novel findings, the minor T790M mutation was signifi-
cantly associated with drug-sensitive EGFR mutations in a 
multivariate analysis. Previous reports have described that 
drug-sensitive EGFR mutations and the T790M mutation 
generally occur in cis (31-33), although the statistical relation-
ship between minor T790M mutation and drug-sensitive EGFR 
mutations has never been revealed in clinical samples. Our 
present study is, to the best of our knowledge, the first report 
to confirm that the minor T790M mutation was significantly 
associated with drug-sensitive EGFR mutations in lung adeno-
carcinomas. To understand this situation, two issues should be 
discussed: i) the relationship between drug-sensitive EGFR 
mutations and the T790M mutation, and ii) the presence of the 
T790M mutation as a minor population. Regarding the first 
issue, while the reason for this association is unknown, lung 
cancers with germ-line EGFR mutations such as T790M (31), 
V843I (34), and R776H (35) are accompanied by additional 
EGFR mutations in the development of lung cancer, suggesting 
that EGFR mutations themselves cause genetic instability, 
thereby predisposing cells to additional mutations within the 
gene (34). The second issue can be explained by the following 
hypothesis. During the carcinogenic process of EGFR-mutant-
related lung cancer, drug-sensitive EGFR mutations occur first 
in the progenitor cells of lung cancer, followed by the T790M 
mutation. At this stage, the tumor consists of a heterogeneous 
population of drug-sensitive EGFR mutant cells with or 
without the T790M mutation. Previous studies have reported 
that drug-sensitive EGFR mutant cells with an additional 
T790M mutation exhibit an indolent progression, indicating 
that the possession of the T790M mutation is a disadvantage 
for cell proliferation (36). This fact suggests that cancer cells 
with only drug-sensitive EGFR mutations may be dominant in 
tumors, in addition to those with T790M and drug-sensitive 
EGFR mutations as a minor population.
Our study also suggested that the T790M mutation 
tended to be associated with a smoking history in this study. 
Drug-sensitive EGFR mutations are known to be frequent 
in never-smokers with NSCLCs. However, drug-sensitive 
EGFR mutations themselves have not been reported to be 
associated with a never-smoking habit (30). Matsuo et al (30) 
indicated that EGFR mutations presumably occur in both 
smokers and never-smokers with a similar incidence, but other 
smoking-related mutations such as TP53 or KRAS mutations 
preferentially occur in smokers resulting in the enrichment 
of the prevalence of EGFR mutations in never-smokers. In 
fact, the average mutation frequency has been reported to 
be >10-fold higher in smokers than in never-smokers (37). 
Considering these observations, the EGFR mutation at codon 
Table III. Multivariate analysis of the minor T790M mutation-
related factors.
Variables OR (95% CI) P-value
Age (years)
  (<68 vs. ≥68) 1.0 (0.4-2.6) 1.0
Gender
  (Male vs. female) 0.6 (0.2-2.5) 0.5
Smoking history
  (Smoker vs. never-smoker) 3.8 (0.9-18) 0.08
Drug-sensitive EGFR mutation
  (Mutant vs. wild) 3.0 (1.0-9.0) 0.04
OR, odds ratio; CI, confidence interval. Drug-sensitive EGFR muta-
tion include detection of exon19 deletions and the L858R mutation.
Table IV. Multivariate analysis for recurrence and mortality.
 PFS OS ------------------------------------------------------------------ ----------------------------------------------------------------
Variables HR (95% CI) P-value HR (95% CI) P-value
Age (<68 vs. ≥68 years) 0.3 (0.1-0.6) <0.01 0.3 (0.1-0.9) 0.02
Gender (Male vs. female) 0.7 (0.2-1.9) 0.4 1.0 (0.3-3.6) 0.9
Smoking history 2.3 (0.8-7.3) 0.1 2.1 (0.6-8.5) 0.3
  (Smoker vs. never-smoker)
Pathological stage (I vs. II-IV) 0.2 (0.09-0.4) <0.01 0.2 (0.05-0.4) <0.01
Drug-sensitive EGFR mutation 1.0 (0.4-2.2) 1.0  0.5 (0.1-1.4) 0.2
  (Mutant vs. wild)
T790M mutation 0.5 (0.08-1.8) 0.3 1.7 (0.4-5.9) 0.4
  (Mutant vs. wild)
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval. Drug-sensitive EGFR mutations include detec-
tion of exon19 deletions and the L858R mutation.
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790, unlike drug-sensitive EGFR mutations, might be suscep-
tible to tobacco-related carcinogens.
In conclusion, we revealed an association between the 
minor T790M mutation and clinicopathological factors in 
surgically resected lung adenocarcinoma patients without 
a history of EGFR-TKI treatment using our novel, highly 
sensitive assay. Minor T790M mutations are independently 
associated with drug-sensitive EGFR mutations.
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